Alphatec Holdings, Inc.
Alphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.
Alphatec Holdings (Nasdaq: ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year. Surgical revenue was $196 million, up 17%, driven by 20% case volume growth. Adjusted EBITDA was $36 million, 17% of revenue. The company reaffirmed its 2026 outlook: revenue about $882 million and adjusted EBITDA about $140 million.
Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSB
Over the past 7 days, alphai's AI scored 3 news stories mentioning ATEC (Alphatec Holdings, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ATEC coverage spans earnings, financial news and corporate actions.
In the last 30 days, ATEC insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($79K). The most active reporter was Marshall Tyson Eliot, GENERAL COUNSEL & CORP. SEC., with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance upgrades and margin expansion signals improve near-term earnings power, but revenue-per-case softness and biologics attachment remain key swing factors.
Q2 growth and reaffirmed revenue outlook with higher adjusted EBITDA guidance suggest improving operating leverage and cash generation.
The 8-K provides fresh quarterly performance plus an updated full-year adjusted EBITDA guide, which can reprice near-term expectations for profitability and cash generation.
Analyst initiation frames ATEC as an undervalued, durable-growth entry point, but it is not a new company-specific operational datapoint.
This is a corporate governance/compensation filing tied to director/officer actions and equity plan administration, not an operating or financial update.
alphai scores every news story that mentions ATEC with an AI model for sentiment and relevance, and aggregates insider trades from Alphatec Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.
6 min readAlphatec Holdings (Nasdaq: ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year. Surgical revenue was $196 million, up 17%, driven by 20% case volume growth. Adjusted EBITDA was $36 million, 17% of revenue. The company reaffirmed its 2026 outlook: revenue about $882 million and adjusted EBITDA about $140 million.
4 min readAlphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSB
6 min readStephens initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with an Overweight rating and a $15.00 price target. The firm says Alphatec’s spine surgery strategy focuses on proceduralization and integrated technologies to reduce outcome variability. It cites ATEC’s underperformance, trading at $8.06, and notes mixed Q1 2026 results and analyst target changes.
4 min readAlphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 atec-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 ALPHATEC HOLDINGS, INC. 2026 EQUITY INCENTIVE PLAN ARTICLE I Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to
3 min readAlphatec Holdings (ATEC) reported Q1 2026 results on May 5, with total revenue up 14% to $192 million and surgical revenue up 17%. The company posted non-GAAP adjusted EBITDA of $21 million and said a new bank facility would cut annual interest expense by over $6 million and extend maturities to 2031. For 2026, it expects revenue of about $882 million and adjusted EBITDA of about $134 million.
4 min readAlphatec Holdings (ATEC) saw two analyst price-target cuts on May 7 while ratings stayed Overweight. Barclays lowered its target to $24 from $27, citing confidence in long-term growth despite near-term operational issues. Piper Sandler cut its target to $14 from $25 after first-quarter results missed expectations due to a weak EOS quarter and softer revenue per case from product mix headwinds.
3 min readAlphatec Holdings, Inc. director Keith Valentine purchased 135,000 shares of common stock in open-market transactions between May 7 and May 11, 2026, increasing his direct holdings to 232,271 shares. The shares were bought at weighted average prices ranging from approximately $7.00 to $7.55 per share. This activity signals confidence from Valentine as he committed new capital at prevailing market prices.
2 min readThis article identifies five top healthcare stocks suitable for long-term investment, withAlphatec Holdings, Inc. (NASDAQ: ATEC) being the first discussed. It highlights Alphatec's recent Q1 2026 results, showing surgical and total revenue growth but notes rating adjustments by analysts due to an unexpected miss in its EOS business. Despite some challenges, the company's core surgical business performed well, and it continues to be recommended for its spinal fusion technology products.
3 min readAlphatec (NASDAQ: ATEC) announced strong Q1 2026 growth, with total revenue reaching $192 million and surgical revenue increasing 17% year over year. The company also refinanced its debt with a new syndicated bank facility, securing a $175 million Term Loan A and a $125 million revolver, which is expected to cut annual interest expenses by over $6 million and extend maturities to 2031. Alphatec reaffirmed its 2026 surgical revenue guidance of $805 million and targets total revenue of $882 million, with an adjusted EBITDA of $134 million and at least $20 million in free cash flow.
2 min read
